4,901 trials
Wound Healing
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Single Dose Administration (Part A) — 2; 3; 1; 0 Participants
Healthy Volunteers
Primary: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC — 433.4; 560.3 microgram*day per…
Healthy
Primary: The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)…
Anxiety Disorders
Primary: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of Paroxetine Following Single Oral Dose in Healthy Chinese…
Psoriasis
Primary: Number of Participants With Hematology Abnormalities of Potential Clinical Importance (PCI) — 3; 0; 0; 0 Participants
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
Soft Tissue Sarcoma
Primary: Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood — 846.93; 820.11 percent change
Healthy Volunteers
Primary: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC — 493.5; 485.8 microgram*day per…
Hypertension
Primary: Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up — 5; 0; 5; 1 Count of Participants
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
Advanced Cancer
Primary: Number of Participants With Clinically Significant Effects — 0; 1; 0; 0 Participants
Irritable Bowel Syndrome
Primary: Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1 — 0; 1; 0; 0 Participants
Hypertension
Primary: Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants — 100.0; 100.0; 80.0; 33.3 Percentage of Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With 1 or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants
Advanced Solid Malignancies · Hematologic Malignancies
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 8 mg (QD×3d QW)